David Goldenberg držitelem ocenění SNM
DAVID M. GOLDENBERG RECEIVES HIGHEST AWARD FROM SOCIETY OF NUCLEAR MEDICINE - 2005 Paul C. Aebersold Award for Outstanding Achievement -
Morris Plains, NJ, June 20, 2005 - Immunomedics, Inc. (Nasdaq: IMMU), a leading biopharmaceutical company focused on developing monoclonal antibodies, announced today that its founder and Chairman of the Board of Directors, David M. Goldenberg, Sc.D., M.D., was the recipient of the 2005 Paul C. Aebersold Award at the 52nd Annual Meeting of the Society of Nuclear Medicine in Toronto, Canada.
"I am humbled to be among these giants of nuclear medicine. I am especially grateful to the Society for recognizing my contributions to basic science applied to nuclear medicine," commented Dr. Goldenberg.
In awarding Dr. Goldenberg its highest honor, the Society of Nuclear Medicine recognized his contributions to the basic science of nuclear medicine by his pioneering work in the development of radiolabeled antibodies for various applications in the detection, diagnosis, and therapy of solid tumors, such as colorectal, pancreatic, lung, breast, and ovarian cancers, as well as certain hematologic cancers, such as lymphoma and multiple myeloma.
About Dr. David M. Goldenberg
Dr. David M. Goldenberg is the founder of Immunomedics and is currently the Chairman of its Board of Directors. He also serves as Chairman of the Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics. Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg (Germany) School of Medicine (M.D.). He has written or co-authored more than 1,500 journal articles, book chapters and abstracts on cancer research, detection and treatment, and has researched and written extensively in the area of radioimmunodetection and radioimmunotherapy using radiolabeled antibodies. In addition to his position with Immunomedics, Dr. Goldenberg is President of the Center for Molecular Medicine and Immunology ("CMMI"), an independent non-profit research center, and its clinical unit, the Garden State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an "Outstanding Investigator Grant" award from the National Cancer Institute for his work in radioimmunodetection, and in 1986 he received the New Jersey Pride Award in Science and Technology. Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology, and in 2002, the Elis Bervin Lectureship and Medal from the Swedish Medical Society and the Swedish Oncology Society for his contributions to the development of radiolabeled monoclonal antibodies used in the imaging and treatment of cancer. The International Society for Oncodevelopmental Biology and Medicine also named Dr. Goldenberg the co-recipient of its 1994 Abbott Award.
Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two pivotal Phase III trials, for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus treatment drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 90 issued patents in the United States, and more than 250 other issued patents worldwide, protects its product candidates and technologies. Visit the Company's web site at http://www.immunomedics.com.